glun 1

GluN1/3A-IN-1 (Compound GM-10) is an inhibitor of the GluN1/GluN3A NMDA receptors. It exhibits potent inhibitory activity against GluN1/GluN3A with an IC50 of 0.98 µM. The compound targets the pre-M1 region, forming hydrogen bonds with key residues. GluN1/3A-IN-1 is applicable in the study of neurological conditions associated with GluN1/GluN3A.

GluN1 (359-378), an antibody targeting the N-methyl-D-aspartate receptor (NMDAR), can cross the blood-brain barrier and is used in research on immune-based therapies for anti-NMDAR encephalitis [1].

GluN1 (356-385) is an antigenic peptide implicated in N-methyl-D-aspartate receptor (NMDAR) encephalitis, shown to decrease NMDAR surface cluster density in hippocampal neurons, and serves as a tool to investigate the pathogenesis of anti-NMDAR encephalitis [1].

L-689560 is widely used as a radiolabeled ligand in binding studies and used to study the roles of NMDA receptors in normal neurological processes as well as in diseases. At the GluN1 glycine binding site, L-689560 is an effective N-methyl-D-aspartate (NM

(RS)-(Tetrazol-5-yl)glycine is a potent and selective N-methyl-D-aspartate (NMDA) receptor agonist that can induce seizure models and Fos expression in mice. Its EC50 values for GluN1/GluN2D and GluN1/GluN2A are 99 nM and 1.7 μM, respectively.

TCN 201 is a selective antagonist of NMDA receptors containing the NR2A subunit.

GluN2B receptor modulator-1 is a potent and selective allosteric negative modulator of the GluN2B subunit of NMDA receptors, exhibiting an IC50 value of 31 nM, enabling spcific modulation of subunit-specific allosteric control over the transmembrane ion channel pores of the NMDARs. providing a valuable tool in neuropharmacology and receptor-specific mechanisms relevant in the study of neurological diseases.

GluN2A Allosteric modulator 1 (Compound 11) is an orally bioavailable compound that effectively crosses the blood-brain barrier and functions as a highly selective negative allosteric modulator of GluN2A. It exhibits an IC50 of 0.042 μM for GluN2A and 13 μM for GluN2B. This compound is useful for research in neurological disorders.

GluN2B-NMDAR Antagonist-1, an orally active compound, functions as a GluN2B-NMDAR antagonist with neuroprotective properties. It is applicable in the research of ischemic injury [1].

TCN 213 is an antagonist of NMDA receptor that has a selective for NR1/NR2A over NR1/NR2B